Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

Inclusion Criteria:

Subject has diagnosis of RA or PsA and indicated for treatment with etanercept per the current label, based on history.
Subject is willing to self-inject per investigator judgement at screening.
Subject has no known history of tuberculosis.

Exclusion Criteria:

Latex allergy.
Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to first study dose of etanercept.
Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening.
Other criteria may apply.